Abstract:Abstract: The tumor suppressor protein p53, a transcription factor playing a key role in cancer prevention, interacts with DNA as its primary means of determining cell fate in the event of DNA damage. When it becomes mutated, it opens damaged cells to the possibility of reproducing unchecked, which can lead to formation of cancerous tumors. Despite its critical role, therapies at the molecular level to restore p53 native function remain elusive, due to its complex nature. Nevertheless, considerable information has been amassed, and new means of investigating the problem have become available. Objectives: We consider structural, biophysical, and bioinformatic insights and their implications for the role of direct and indirect readout and how they contribute to binding site recognition, particularly those of low consensus. We then pivot to consider advances in computational approaches to drug discovery. Materials and methods: We have conducted a review of recent literature pertinent to the p53 protein. Results: Considerable literature corroborates the idea that p53 is a complex allosteric protein that discriminates its binding sites not only via consensus sequence through direct H-bond contacts, but also a complex combination of factors involving the flexibility of the binding site. New computational methods have emerged capable of capturing such information, which can then be utilized as input to machine learning algorithms towards the goal of more intelligent and efficient de novo allosteric drug design. Conclusions: Recent improvements in machine learning coupled with graph theory and sector analysis hold promise for advances to more intelligently design allosteric effectors that may be able to restore native p53-DNA binding activity to mutant proteins. Clinical relevance: The ideas brought to light by this review constitute a significant advance that can be applied to ongoing biophysical studies of drugs for p53, paving the way for the continued development of new methodologies for allosteric drugs. Our discoveries hold promise to provide molecular therapeutics which restore p53 native activity, thereby offering new insights for cancer therapies. Graphical abstract: Structural representation of the p53 DBD (PDBID 1TUP). DNA consensus sequence is shown in gray, and the protein is shown in blue. Red beads indicate hotspot residue mutations, green beads represent DNA interacting residues, and yellow beads represent both.

Unraveling The Allosteric Mechanism Of Four Cancer-Related Mutations In The Disruption Of P53-Dna Interaction

Navigating the complexity of p53-DNA binding: implications for cancer therapy

Full-atomistic Molecular Dynamics Analysis of p53 Active Tetramer

Mechanistic Insight into the Destabilization of P53td Tetramer by Cancer-Related R337H Mutation: a Molecular Dynamics Study.

In Silico Screening, Molecular Dynamics Simulation and Binding Free Energy Identify Single-Point Mutations That Destabilize p53 and Reduce Binding to DNA

Gain of Function of P53 Cancer Mutants in Disrupting Critical DNA Damage Response Pathways

Targeting Mouse Double Minute 2: Current Concepts in DNA Damage Repair and Therapeutic Approaches in Cancer.

Modeling the Etiology of p53-mutated Cancer Cells

The molecular mechanism of action of methylene quinuclidinone and its effects on the structure of p53 mutants

p53's Multifaceted Role in the DNA Damage Response and Tumor Treatment Strategies

Small Molecule Agents Targeting the P53-Mdm2 Pathway for Cancer Therapy

Functional Diversity of P53 in Human and Wild Animals

Conformational Stability and Dynamics of the Cancer‐associated Isoform Δ133p53β Are Modulated by P53 Peptides and P53‐specific DNA

Unraveling the Role of TP53 in Colorectal Cancer Therapy: From Wild-Type Regulation to Mutant

Differential gene expression in cells with different p53 mutations identifies genome-wide p53 targets and shows distinct modulation of cellular pathways in response to DNA damage

Zinc shapes the folding landscape of p53 and establishes a pathway for reactivating structurally diverse cancer mutants

Network effect of Wt-mutant p53 interactions and implications on p53 gene therapy.

Novel Allosteric Mechanism of Dual p53/MDM2 and p53/MDM4 Inhibition by a Small Molecule

Structural basis of p53 inactivation by cavity-creating cancer mutations and its implications for the development of mutant p53 reactivators

Molecular dynamics-based computational investigations on the influence of tumor suppressor p53 binding protein against other proteins/peptides

Structural effects and competition mechanisms targeting the interactions between p53 and MDM2 for cancer therapy